Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43851   clinical trials with a EudraCT protocol, of which   7283   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2022-001362-35
    Sponsor's Protocol Code Number:C4671034
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2022-07-27
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2022-001362-35
    A.3Full title of the trial
    AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, 3-ARM STUDY TO INVESTIGATE NIRMATRELVIR/RITONAVIR IN NONHOSPITALIZED PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH SYMPTOMATIC COVID-19 WHO ARE IMMUNOCOMPROMISED
    ESTUDIO INTERVENCIONAL DE EFICACIA Y SEGURIDAD, DE FASE II, ALEATORIZADO, DOBLE CIEGO, DE TRES GRUPOS PARA INVESTIGAR NIRMATRELVIR/RITONAVIR EN PARTICIPANTES INMUNOCOMPROMETIDOS, NO HOSPITALIZADOS, DE AL MENOS 12 AÑOS DE EDAD CON COVID-19 SINTOMÁTICO
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Study to Learn About the Study Medicines Called Nirmatrelvir/Ritonavir in People at Least 12 Years of Age With COVID-19 Who Are Immunocompromised
    Estudio para conocer los medicamentos del estudio denominados nirmatrelvir/ritonavir en
    personas con COVID-19 de al menos 12 años inmunodeprimidos
    A.4.1Sponsor's protocol code numberC4671034
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorPfizer Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportPfizer Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationPfizer Inc.
    B.5.2Functional name of contact pointClinical Trials.gov Call Centre
    B.5.3 Address:
    B.5.3.1Street Address235 East 42nd Street
    B.5.3.2Town/ cityNew York
    B.5.3.3Post code10017
    B.5.3.4CountryUnited States
    B.5.4Telephone number+18007181021
    B.5.6E-mailClinicalTrials.gov_Inquiries@pfizer.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name RITONAVIR
    D.2.1.1.2Name of the Marketing Authorisation holderCamber Pharmaceuticals, Inc
    D.2.1.2Country which granted the Marketing AuthorisationUnited States
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRitonavir
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRitonavir
    D.3.9.1CAS number 155213-67-5
    D.3.9.4EV Substance CodeSUB10342MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNirmatrelvir
    D.3.2Product code PF-07321332
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNirmatrelvir
    D.3.9.3Other descriptive nameNirmatrelvir
    D.3.9.4EV Substance CodeSUB220919
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number150
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    SARS-CoV-2 Infection
    Infección SARS-CoV-2
    E.1.1.1Medical condition in easily understood language
    COVID-19
    COVID-19
    E.1.1.2Therapeutic area Diseases [C] - Virus Diseases [C02]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 23.1
    E.1.2Level PT
    E.1.2Classification code 10084460
    E.1.2Term COVID-19 treatment
    E.1.2System Organ Class 10042613 - Surgical and medical procedures
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To describe the effect of nirmatrelvir/ritonavir on viral RNA levels in NP swabs over time for the treatment of COVID-19 in nonhospitalized symptomatic participants ≥12 years of age with COVID-19 who are immunocompromised.
    Describir el efecto de nirmatrelvir/ritonavir sobre los niveles de ARN vírico en hisopos NF a lo largo del tiempo para el tratamiento de la COVID-19 en participantes inmunodeprimidos, sintomáticos, no hospitalizados, ≥ 12
    años con COVID-19.
    E.2.2Secondary objectives of the trial
    • To describe the effect of nirmatrelvir/ritonavir treatment duration on the rate of sustained virologic clearance
    • To describe the effect of nirmatrelvir/ritonavir on viral clearance.
    • To describe the safety and tolerability of nirmatrelvir/ritonavir
    • To describe the effect of nirmatrelvir/ritonavir on hospitalization and all-cause mortality
    • To evaluate nirmatrelvir/ritonavir for the duration and severity of signs and symptoms
    • To describe COVID-19 related healthcare resource utilization
    - Describir el efecto de la duración del tratamiento con nirmatrelvir/ritonavir sobre la tasa de aclaramiento virológico
    - Describir el efecto de nirmatrelvir/ritonavir en el aclaramiento vírico
    - Describir la seguridad y tolerabilidad de nirmatrelvir/ritonavir
    - Describir el efecto de nirmatrelvir/ritonavir en la hospitalización y la mortalidad total
    - Evaluar nirmatrelvir/ritonavir durante la duración y gravedad de los signos y síntomas
    - Describir la utilización de los recursos sanitarios
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Participants aged 12 years or older and weighing ≥40 kg at screening (Appendix 9, Section 10.9.1).
    - Refer to Appendix 4 for reproductive criteria for female (Section 10.4.2) participants.
    2. Confirmed SARS-CoV-2 infection as determined by RT-PCR or other acceptable test method (see Appendix 9, Section 10.9.2) in any specimen collected within 5 days prior to randomization.
    3. ≥1 signs/symptoms attributable to COVID-19 present on the day of randomization (Appendix 9, Section 10.9.3).
    4. Immunocompromised (Appendix 9, Section 10.9.4).
    1. Participantes a partir de los 12 años y con un peso ≥ 40 kg en la selección
    - Consulte el protocolo para ver los criterios de reproducción de las participantes de
    sexo femenino.
    2. Infección confirmada por SARS-CoV-2 determinada por RT-PCR en cualquier muestra obtenida en las 5 horas anteriores a la aleatorización.
    3. ≥ 1 signos/síntomas atribuibles a la COVID-19 presentes el día de la aleatorización
    4. Inmunodeprimidos
    E.4Principal exclusion criteria
    1. Current need for hospitalization or anticipated need for hospitalization within 24h after randomization in the clinical opinion of the site investigator.
    2. Known medical history of active liver disease (other than nonalcoholic hepatic steatosis), including chronic or active hepatitis B or C infection, primary biliary cirrhosis, Child-Pugh Class C, or acute liver failure.
    3. History of hypersensitivity or other contraindication to any of the components of the study interventions, as determined by the investigator.
    4. Suspected or confirmed concurrent active systemic infection other than COVID-19 that may interfere with the evaluation of response to the study intervention.
    5. Any comorbidity requiring hospitalization and/or surgery within 7 days prior to study entry, or that is considered life threatening within 30 days prior to study entry, as determined by the investigator.
    6. Receiving dialysis or have known age-specific eGFR or eCrCl <30 mL/min/1.73 m2 at screening as measured by a serum creatinine point of care device.
    7. Oxygen saturation of <92% on room air obtained at rest within 24h prior to randomization.
    8. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behaviour or laboratory abnormality that may increase the risk of study participation or, in the investigator’s judgment, make the participant inappropriate for the study.
    9. Current use of any prohibited concomitant medication(s).
    10. Current or previous administration with an investigational product (drug or vaccine) within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer). Authorized or products with conditional approval are not considered investigational.
    11. Prior participation in this trial.
    12. Females who are pregnant up to <14 weeks gestation. Pregnancy ≥14 weeks is not exclusionary.
    13. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
    1. Necesidad actual de hospitalización o necesidad anticipada de hospitalización dentro de las 24 horas siguientes a la aleatorización, según la opinión clínica del investigador del centro.
    2. Antecedentes médicos conocidos de hepatopatía activa (aparte de la esteatosis hepática no alcohólica); se incluye infección crónica o activa por hepatitis B o C, cirrosis biliar primaria, clase Child-Pugh C o insuficiencia hepática aguda.
    3. Antecedentes de hipersensibilidad u otra contraindicación a cualquiera de los componentes del tratamiento del estudio, según lo determinado por el investigador.
    4. Infección sistémica activa concurrente sospechada o confirmada que no sea COVID- 19 y que pueda interferir con la evaluación de la respuesta al tratamiento del estudio.
    5. Cualquier enfermedad concomitante que requiera hospitalización o cirugía dentro de los 7 días anteriores a la inclusión en el estudio, o que se considere potencialmente mortal en los 30 días anteriores a la inclusión en el estudio, según lo determinado por el investigador.
    6. Recibir diálisis o tener un eGFR o eCrCl específico de la edad < 30 ml/min/1,73 m2 en la selección según lo medido por un dispositivo de análisis de diagnóstico inmediato.
    7. Saturación de oxígeno < 92 % en el aire de la habitación obtenida en reposo dentro de las 24 horas anteriores a la aleatorización.
    8. Otras enfermedades o trastornos psiquiátricos, incluidas las ideas y conductas de suicidio recientes (durante el último año) o activas, o anomalías de laboratorio que puedan aumentar el riesgo de participar en el estudio o, según la opinión del investigador, causar que el participante resulte inadecuado para el estudio.
    9. Uso actual de cualquier medicamento concomitante prohibido.
    10. Administración previa o actual de cualquier producto en fase de investigación (vacuna o medicamento) dentro de los 30 días (o según lo determinen los requisitos locales) o 5 semividas antes de la primera dosis del tratamiento utilizado en este estudio (el periodo que sea más largo). Los productos autorizados o con aprobación condicional no se consideran en investigación.
    11. Participación previa en este ensayo.
    12. Mujeres que estén embarazadas hasta < 14 semanas de gestación. El embarazo de ≥ 14 semanas no es excluyente.
    13. Personal del centro del investigador implicados directamente en la realización del estudio y sus familiares; personal del centro que sean supervisados de algún modo por el investigador y el promotor implicados directamente en la realización del estudio, incluidos sus familiares.
    E.5 End points
    E.5.1Primary end point(s)
    Proportion of participants with sustained NP swab SARS-CoV-2 RNA <LLOQ (defined as <2.0 log10 copies/mL) from the end of active treatment through Day 44.
    Proporción de participantes con ARN del SARS-CoV-2 en hisopo NF < LLOQ (definido como <2,0 log10 copias/ml) desde el final del tratamiento activo hasta el día 44.
    E.5.1.1Timepoint(s) of evaluation of this end point
    The proportion of participants with sustained NP swab SARS-CoV-2 RNA <LLOQ (defined as <2.0 log10 copies/mL) from the end of active treatment through Day 44 in nonhospitalized, symptomatic patients ≥12 years of age with COVID-19 who are immunocompromised. This will be estimated without regard to study treatment discontinuation and excluding data after the date of nonstudy antiviral or monoclonal antibody start for participants receiving non-study antiviral or monoclonal antibody therapy postbaseline for the treatment of COVID-19.
    La proporción de participantes con ARN del SARS-CoV-2 en hisopo NF < LLOQ (definido como <2,0 log10 copias/ml) desde el final del tratamiento activo hasta el día 44 en pacientes inmunodeprimidos no hospitalizados y sintomáticos ≥ 12 años con COVID-19. Se calculará sin tener en cuenta la interrupción del tratamiento del estudio y con exclusión de los datos posteriores a la fecha de inicio del antivírico o anticuerpo monoclonal del estudio para los participantes que reciban tratamiento antivírico o anticuerpo monoclonal que no sea del estudio
    después del inicio para el tratamiento de la COVID-19.
    E.5.2Secondary end point(s)
    • Time to first NP swab SARS-CoV-2 RNA<LLOQ (<2.0 log10 copies/mL) for participants with NP swab SARS-CoV-2 RNA ≥LLOQ at baseline.
    • Time to sustained NP swab SARS CoV-2 RNA <LLOQ (<2.0 log10 copies/mL) through Day 44 for participants with NP swab SARS-CoV-2 RNA ≥LLOQ at baseline.
    • Proportion of participants with SARS-CoV-2 RNA <LLOQ in plasma over time.
    • Proportion of participants with SARS-CoV-2 RNA level in NP swabs <2.0 log10 copies/mL at each study visit through Day 44.
    • Change from baseline in SARS CoV-2 RNA level in NP swabs and in plasma over time.
    • Rebound in SARS-CoV-2 RNA level in NP swabs at follow up (ie, any study visit after end of treatment through Day 44) that is defined as a half (0.5) log10 copies/mL increase or greater in SARS-CoV-2 RNA level relative to end of treatment SARS-CoV-2 RNA level based on treatment regimen, with a follow-up viral RNA level ≥2.5 log10 copies/mL.
    • Incidence of TEAEs.
    • Incidence of SAEs and AEs leading to discontinuations.
    • Proportion of participants with COVID-19-related hospitalization >24 hours, or death from any cause through Day 28.
    • Proportion of participants with death (all cause) through Week 24.
    • Proportion of participants with COVID-19-related hospitalization of any duration.
    • Proportion of participants with COVID-19-related ICU admission of any duration.
    • Proportion of participants requiring invasive mechanical ventilation or ECMO.
    • Number of days in hospital and ICU stay in participants with COVID 19 related hospitalization.
    • Number of COVID-19-related medical visits through Day 44 and through Week 24.
    • Duration of each targeted COVID-19 signs/symptoms. Proportion of participants with severe signs/symptoms attributed to COVID-19 through Day 44.
    • Nirmatrelvir and ritonavir PK in plasma and whole blood (if feasible).
    • Hora del primer ARN del SARSCoV- 2 en hisopo NF< LLOQ (<2,0 log10 copias/ml) para los participantes con ARN del SARS-CoV-2 en hisopo NF ≥ LLOQ en el momento inicial.
    • Tiempo hasta hisopo NP sostenido con ARN del SARS-CoV-2 < LLOQ (<2,0 log10 copias/ml) hasta el día 44 para los participantes con ARN del SARS-CoV-2 en hisopos NF ≥ LLOQ en el momento inicial.
    • Proporción de participantes con ARN del SARS-CoV-2 < LLOQ en plasma a lo largo del tiempo.
    • Proporción de participantes con nivel de ARN del SARS-CoV-2 en hisopos NF < 2,0 log10 copias/ml en cada visita del estudio hasta el día 44.
    • Cambio respecto al inicio en el nivel de ARN del SARS-CoV-2 en hisopos NF y en plasma a lo largo del tiempo.
    • Rebote del nivel de ARN del SARSCoV- 2 en hisopos NF en el seguimiento (es decir, cualquier visita del estudio después de finalizar el tratamiento hasta el día 44) que se define como medio (0,5) aumento del log10 copias/ml o mayor en el nivel de ARN del SARS-CoV-2 en relación con el nivel de ARN del SARS-CoV- 2 del final del tratamiento basado en la pauta posológica, con un nivel de ARN vírico de seguimiento de ≥ 2,5 log10 copias/ml.
    • Incidencia de AAET.
    • Incidencia de AAG y AA que conducen a interrupciones.
    •Proporción de participantes hospitalizados por la COVID-19 durante > 24 horas o muerte por cualquier causa hasta el día 28.
    • Proporción de participantes con muerte (todas las causas) hasta la semana 24.
    • Proporción de participantes hospitalizados por la COVID-19 de cualquier duración.
    • Proporción de participantes con ingreso en la UCI por la COVID-19 de cualquier duración.
    • Proporción de participantes que requieren ventilación mecánica invasiva o ECMO.
    • Número de días de hospitalización y estancia en la UCI de los participantes hospitalizados por la COVID-19.
    • Número de visitas médicas relacionadas con la COVID-19 hasta el día 44 y la semana 24.
    • Duración de los signos y los síntomas de la COVID-19. Proporción de participantes con signos y síntomas graves atribuidos a la COVID-19 hasta el día 44.
    • FC de nirmatrelvir/ritonavir en plasma y sangre completa (si es posible).
    E.5.2.1Timepoint(s) of evaluation of this end point
    Not applicable.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA33
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Brazil
    Canada
    Mexico
    United States
    Bulgaria
    Spain
    Hungary
    Slovakia
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Último paciente - última visita
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial months15
    E.8.9.2In all countries concerned by the trial days14
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 8
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 8
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 112
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 30
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women Yes
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Adolescents (12-17 years)
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state150
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 90
    F.4.2.2In the whole clinical trial 150
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    No intervention will be provided to study participants at the end of
    their study participation. Participants will be treated for their condition
    according to local standard of care.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-11-29
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-11-02
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA